DexCom, Inc. (DXCM) hit a jubilant high note, tuning in at a 52-week peak of $142.00 on Mar 26, only to wind down slightly to $139.93 at the closing bell. This crescendo comes on the heels of a noteworthy upswing, with the Zacks Rank #2 (Buy) stock blooming by 20.6% over the past year, outshining the industry’s 8.8% uptick and the S&P 500’s 31% expansion.
Through the prism of the last half-decade, DexCom has orchestrated an earnings symphony, soaring by 61.1% while the industry hummed along at an 8.5% pace. The company’s long-term growth projection of 33.1% harmonizes melodiously with the industry’s more muted 14.2% forecast. A virtuoso in the earnings realm, DexCom has serenaded investors with beats that consistently outpaced the Zacks Consensus Estimate over four quarters, with an average surprise swell of 32.8%.
The stock’s melody has been carried on a strong breeze, with a robust product mix tuning into an uptrend. The operatic optimism, fueled by a stellar fourth-quarter performance, promises a harmonious future despite competitive counterpoint and supply chain challenges.
Image Source: Zacks Investment Research
Let’s unravel the harmony.
Key Growth Drivers
Strong Product Portfolio: DexCom’s resilient suite of products is striking a chord with investors’ hearts, fostering optimism. Recently, the company’s Stelo received FDA clearance for non-prescription use, heralding a new era in glucose monitoring.
In a recent symphony of success, DexCom unveiled its latest continuous glucose monitoring system, Dexcom ONE+, offering a harmonious blend of technology and accessibility across European markets.
Coverages: Investor spirits soar on the wings of increasing coverage for DexCom’s products. The G7 CGM System’s broad insurance coverage in the U.S., coupled with positive payer policies, is a prelude to a future harmoniously orchestrated.
By the end of 2023, leading third-party payors had extended coverage for CGM devices, striking a chord with DexCom’s orchestrated success. Contracted rates with payors ensure a symphonic note in DexCom’s revenue streams.
Strong Q4 Results: DexCom’s magnetic fourth-quarter 2023 performance reverberates with optimism. Robust revenues and geographical resonance painted a picture of success. The submission of a direct-to-watch feature to the FDA reflects the company’s continual drumbeat of innovation.
Downsides
Supply Constraints: DexCom’s manufacturing crescendo faces the challenge of variability and resource constraints, casting a shadow of uncertainty. Such challenges could lead to discord in product quality, timing, and resource allocation, potentially disrupting manufacturing.
Stiff Competition: The competitive landscape in glucose monitoring is akin to a musical duel, with market dynamics and new product entries constantly changing the tune. Several rivals are marching to the rhythm of continuous glucose monitoring, challenging DexCom’s position in the spotlight.
Other Key Picks
In the symphonic landscape of the medical sector, standout performers like DaVita Inc. DVA, Cardinal Health, Inc. CAH, and Cencora, Inc. COR deserve a standing ovation.
DaVita, currently holding the prestigious Zacks Rank #1 (Strong Buy), boasts an estimated long-term growth rate of 12.1%. With a winning streak of earnings beats over the past four quarters, DaVita’s performance is nothing short of a musical crescendo.
Cardinal Health, carrying a Zacks Rank of 2, is hitting the right notes with an estimated long-term growth rate of 14.2%. Allegro earnings surprises over four quarters underline a consistent lyrical performance.
Cencora, also bearing a Zacks Rank of 2, is hitting the right chords with an estimated long-term growth rate of 9.8%. Earnings surprises over four quarters underscore the company’s symphonic success.
7 Best Stocks for the Next 30 Days
Maestros of the market present 7 elite stocks handpicked from Zacks Rank #1 Strong Buys, deemed “Most Likely for Early Price Pops.” Since 1988, this exclusive list has outperformed the market, orchestrating an average annual gain of +24.2%. Strike a chord with these stellar picks today.
DaVita Inc. (DVA) Free Stock Analysis Report
Cardinal Health, Inc. (CAH) Free Stock Analysis Report
DexCom, Inc. (DXCM) Free Stock Analysis Report
Cencora, Inc. (COR) Free Stock Analysis Report
Read the full article on Zacks.com here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
